Persistent Depressive Disorder Research & Evidence-Based Practice 4 — Questions and Answers
Question 1: Which neurotransmitter system has the strongest evidence base from PDD research as a primary target for pharmacotherapy?
- Serotonergic system, with secondary involvement of norepinephrine and dopamine (Correct answer)
- Exclusively the GABAergic system
- Opioid system as the primary driver
- Histaminergic system with serotonin as secondary
Correct answer: Serotonergic system, with secondary involvement of norepinephrine and dopamine
Research most consistently implicates the serotonergic system in PDD, though evidence increasingly supports multi-neurotransmitter involvement including norepinephrine and dopamine.
Question 2: Evidence-based practice guidelines from APA recommend which assessment tool as part of a comprehensive PDD evaluation?
- Structured Clinical Interview for DSM (SCID) to confirm diagnosis and rule out bipolar spectrum (Correct answer)
- Beck Depression Inventory alone is sufficient for diagnosis
- Neuroimaging required before diagnosis can be confirmed
- Genetic testing to identify serotonin transporter polymorphisms
Correct answer: Structured Clinical Interview for DSM (SCID) to confirm diagnosis and rule out bipolar spectrum
APA guidelines recommend structured clinical interviews like the SCID to reliably diagnose PDD and systematically rule out bipolar spectrum disorders, which significantly affect treatment.
Question 3: Research comparing SSRIs to SNRIs for PDD treatment shows which pattern in head-to-head trials?
- Comparable efficacy with individual differences determining which class works best for a given patient (Correct answer)
- SNRIs are consistently superior to SSRIs across all PDD populations
- SSRIs are ineffective for PDD; only SNRIs show benefit
- MAOIs outperform both SSRIs and SNRIs in all studies
Correct answer: Comparable efficacy with individual differences determining which class works best for a given patient
Head-to-head trials show comparable overall efficacy between SSRIs and SNRIs for PDD, supporting individualized treatment selection based on patient factors and tolerability.
Question 4: A research team studying PDD biomarkers would most likely find which inflammatory marker elevated compared to healthy controls?
- C-reactive protein (CRP) and interleukin-6 (IL-6) (Correct answer)
- Tumor necrosis factor alpha (TNF-α) exclusively
- No inflammatory markers differ from healthy controls
- Only white blood cell count is elevated
Correct answer: C-reactive protein (CRP) and interleukin-6 (IL-6)
Research consistently finds elevated CRP and IL-6 in chronic depression including PDD, supporting the inflammatory hypothesis of depressive disorder chronicity.
Question 5: Studies examining predictors of non-response to antidepressants in PDD patients identify which factor as most strongly associated with poor medication response?
- Comorbid personality disorder, particularly Cluster C personality disorders (Correct answer)
- Female sex assigned at birth
- Age of onset after 40 years
- Urban versus rural residence
Correct answer: Comorbid personality disorder, particularly Cluster C personality disorders
Research consistently identifies comorbid personality disorders, especially Cluster C, as among the strongest predictors of antidepressant non-response in PDD.
Question 6: What does research on the STAR*D trial inform us about PDD treatment, even though STAR*D focused on MDD?
- Chronic depression characteristics (like those in PDD) predict lower remission rates and require more treatment steps (Correct answer)
- Dysthymia remits faster than acute MDD according to STAR*D data
- All antidepressants show equal efficacy regardless of chronicity
- STAR*D data has no relevance to PDD treatment decisions
Correct answer: Chronic depression characteristics (like those in PDD) predict lower remission rates and require more treatment steps
STAR*D found that chronic depression features, present in PDD, predict lower remission rates at each treatment step, underscoring the need for persistent, multi-step treatment approaches.
Question 7: In research on exercise as an adjunctive treatment for PDD, what level of evidence currently exists?
- Moderate evidence supports aerobic exercise as a useful adjunct, though RCTs specific to PDD are limited (Correct answer)
- Level I evidence from multiple large RCTs specific to PDD
- No evidence supports exercise for any depressive condition
- Exercise is contraindicated in PDD due to fatigue symptoms
Correct answer: Moderate evidence supports aerobic exercise as a useful adjunct, though RCTs specific to PDD are limited
Exercise has moderate evidence as an antidepressant adjunct in depressive disorders generally, though PDD-specific RCTs are limited, warranting clinical consideration with appropriate caveats.
Persistent Depressive Disorder Research & Evidence-Based Practice 4
Which neurotransmitter system has the strongest evidence base from PDD research as a primary target for pharmacotherapy?